STUDY THE NUTRITIONAL AND THERAPEUTIC EFFECT OF FLAXSEED, SUNFLOWER AND PUMPKIN SEEDS ON THE LEVEL OF BLOOD LIPIDS AND WEIGHT GAIN ON RATS

2019 ◽  
Vol 4 (3) ◽  
pp. 103-123
Author(s):  
M. M. El Sayed ◽  
Fatma G. R. El Hawary
Keyword(s):  
Weight Gain ◽  
Therapeutic Effect ◽  
Blood Lipids ◽  
Pumpkin Seeds

Atractylenolide II-ameliorated hyperlipidemia in mice by regulating AMPK/PPARα/SREBP-1C signaling pathway

2019 ◽  
Vol 9 (5) ◽  
pp. 517-523 ◽  
Author(s):  
Qi Ren ◽  
Ge Fang ◽  
Bin Wang ◽  
Xiaowen Zhou ◽  
Xiantao Li
Keyword(s):  
Body Weight ◽  
Signaling Pathway ◽  
Therapeutic Effect ◽  
Blood Lipids ◽  
Therapeutic Agents ◽  
Enzyme Linked Immunosorbent Assay ◽  
Pathological Changes ◽  
Reduced Body ◽  
Hematoxylin And Eosin ◽  
Hematoxylin And Eosin Staining

In this paper, we present our study on the effect of atractylenolide II on hyperlipidemic model mice. After 8 weeks, the blood of these mice was taken to detect four lipids. Pathological changes were detected in the aortas and livers of the mice. Expression of PPARα and SREBP-1C was detected in the liver by western blot. An enzyme-linked immunosorbent assay was used to detect the effects of atractylenolide II on blood lipids in hyperlipidemia mice. Hematoxylin and eosin staining was used to detect pathological changes in the aortas and livers of mice with hyperlipidemia after treatment with atractylenolide II. Changes in PPARα and SREBP-1C expression were found in mice with dyslipidemia. As the results shown, atractylenolide II administration reduced body weight and hyperlipidemia in hyperlipidemic model mice. In addition, atractylenolide II effectively relieved fat deposition and damage in aortic and liver tissues. Therefore, atractylenolide II had a beneficial therapeutic effect in reducing hyperlipidemia in hyperlipidemic model mice, which may be related to its ability to inhibit SREBP-1C expression by activating PPARα. The molecular mechanism driving the therapeutic effect of atractylenolide II may involve upregulation of PPARα and activation of the AMPK/PPARα/SREBP-1C signaling pathway. Our research demonstrated the development of therapeutic agents that can be used to improve hyperlipidemia.

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

1987 ◽  
Vol 5 (3) ◽  
pp. 496-503 ◽  
Author(s):  
J T Vetto ◽  
M Z Papa ◽  
M T Lotze ◽  
A E Chang ◽  
S A Rosenberg
Keyword(s):  
Weight Gain ◽  
Side Effects ◽  
Serum Creatinine ◽  
Therapeutic Effect ◽  
Interleukin 2 ◽  
Peak Serum ◽  
Control Group ◽  
Lymphokine Activated Killer Cells ◽  
Future Studies ◽  
Lak Cell

In order to evaluate the efficacy of dexamethasone (dex) in reducing the toxicity of therapy with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2), we treated six patients receiving this form of immunotherapy with intravenous (IV) dex, 4 mg every six hours. Compared with a control group of 27 patients not receiving dex with their immunotherapy, these corticosteroid-treated patients were able to tolerate the administration of more IL-2, yet experienced significantly less toxicity. Dyspnea, confusion, fever, mean peak serum creatinine, and bilirubin levels during treatment were significantly reduced in corticosteroid-treated patients, with a corresponding decrease in pruritus in this group as well. Overall weight gain was not different between groups, although a curtailment of weight gain temporally related to dex treatment was seen in some patients. Hematologic side effects, including anemia, eosinophilia, and thrombocytopenia, were not reduced by dex. These results suggest that dex can inhibit at least some of the toxic side effects of LAK cell and IL-2 therapy. Because of the concern that the therapeutic effect may also be abrogated, future studies combining corticosteroids with this form of immunotherapy should be undertaken with caution.

scholarly journals Weight gain in childhood and blood lipids in adolescence

2009 ◽  
Vol 98 (6) ◽  
pp. 1024-1028 ◽  
Author(s):  
Bernardo L Horta ◽  
Cesar G Victora ◽  
Rosângela C. Lima ◽  
Paulo Post
Keyword(s):  
Weight Gain ◽  
Blood Lipids

Effects of methionine addition in soya bean or casein diets supplemented with carrageenan on weight gain and blood lipids in rats

1992 ◽  
Vol 60 (3) ◽  
pp. 361-368
Author(s):  
Justine Mouécoucou ◽  
Christian Villaume ◽  
Hwei-Ming Bau ◽  
Jean-Pierre Nicolas ◽  
Luc Méjean
Keyword(s):  
Weight Gain ◽  
Blood Lipids ◽  
Soya Bean

The use of agomelatine in the reduction of anhedonia and sleep disorders in the course of depression

2021 ◽  
Vol 14 (2) ◽  
pp. 178-181
Author(s):  
Anna Antosik-Wójcińska
Keyword(s):  
Weight Gain ◽  
Sexual Dysfunction ◽  
Sleep Quality ◽  
Sleep Disorders ◽  
Therapeutic Effect ◽  
Clinical Studies ◽  
Emotional Responses ◽  
Pharmacological Profile ◽  
Onset Of Action ◽  
Course Of Depression

Agomelatine is an antidepressant with a unique pharmacological profile, it acting as an agonist of MT1 and MT2 melatoninergic receptors and as an antagonist of the 5-HT2C receptor. The drug has a quick onset of action and a long maintenance of the therapeutic effect, also it is well tolerated. In clinical studies in patients with depression agomelatine reduces anxiety symptoms and improves sleep quality, not causing sedation, weight gain, sexual dysfunction or suppression of emotional responses.

Sign in / Sign up

Export Citation Format

Share Document